StreetInsider.com News Articles

Celularity Highlights Anticipated Quarter One 2027 Opening of Fontaine Vitale as Strategic Partner

Wed, 30 Sep 2026 11:57:00 -0400

FLORHAM PARK, N.J., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a longevity-focused regenerative and cellular medicine company pioneering placental-derived cellular therapies, today highlighted continued progress at Fontaine Vitale, a regenerative medicine and wellness center being developed in the Sanur Special Economic Zone (“Sanur SEZ”) in Bali, Indonesia, in anticipation of its grand opening in the first quarter of 2027.

Developed by Genting Berhad and its Indonesian partners with strategic collaboration and input from Celularity, Fontaine Vitale is designed to serve local and international patients seeking advanced wellness, aesthetics, longevity and

Celularity Highlights Anticipated Quarter One 2027 Opening of Fontaine Vitale as Strategic Partner

Wed, 30 Sep 2026 11:57:00 -0400

Celularity Highlights Anticipated Quarter One 2027 Opening of Fontaine Vitale as Strategic Partner

Wed, 30 Sep 2026 11:57:00 -0400

Celularity Highlights Anticipated Quarter One 2027 Opening of Fontaine Vitale as Strategic Partner

Wed, 30 Sep 2026 11:57:00 -0400

Form 8-K Celularity Inc For: Sep 29

Tue, 29 Sep 2026 17:26:00 -0400

si-local-file:///var/storage/secattach/20260929/27123515.html

Form 10-Q Celularity Inc For: Mar 31

Tue, 29 Sep 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20260929/27123317.html

Celularity names Viome founder Naveen Jain to its board

Tue, 29 Sep 2026 08:30:12 -0400

Celularity Inc. (Nasdaq: CELU), a regenerative medicine company based in Florham Park, N.J., announced that Naveen Jain, founder and chief executive of Viome Life Sciences Inc., will join its board of directors.

Jain's appointment will become effective following completion of the applicable Rule 14f-1 information statement process. Celularity said it expects to announce a fifth board member shortly.

Jain previously founded InfoSpace, Intelius, TalentWise, and Moon Express. At Viome, he applies artificial intelligence and molecular data to personalized health and nutrition.

Robert J. Hariri, M.D., Ph.D., chairman and chief executive of Celularity, said in the statement that Jain "has a track record of

Celularity Announces Naveen Jain to Join Board of Directors

Tue, 29 Sep 2026 08:30:00 -0400

Viome founder and CEO brings a consumer-focused vision for bringing regenerative therapies to more people and advancing proactive health

FLORHAM PARK, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative medicine company, today announced that Naveen Jain, founder and Chief Executive Officer of Viome Life Sciences Inc. (“Viome”), will join its Board of Directors.

Jain founded InfoSpace, Intelius, TalentWise and Moon Express and is the founder and CEO of Viome, which applies AI and molecular data to personalized health and nutrition. He joins Celularity’s Board with a consumer-focused perspective on

Celularity Announces Naveen Jain to Join Board of Directors

Tue, 29 Sep 2026 08:30:00 -0400

Viome founder and CEO brings a consumer-focused vision for bringing regenerative therapies to more people and advancing proactive health

Form SCHEDULE 13D/A Celularity Inc Filed by: Philip & Daniele Barach Family Trust

Mon, 28 Sep 2026 13:14:00 -0400

si-local-file:///var/storage/secattach/20260928/27113118.html

Form 8-K Celularity Inc For: Sep 18

Mon, 28 Sep 2026 06:14:00 -0400

si-local-file:///var/storage/secattach/20260928/27109684.html

Form 4 Celularity Inc For: Sep 23 Filed by: Philip & Daniele Barach Family Trust

Fri, 25 Sep 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260925/27108088.html

Form 4 Celularity Inc For: Sep 23 Filed by: Barach Daniele Wolf

Fri, 25 Sep 2026 16:59:00 -0400

si-local-file:///var/storage/secattach/20260925/27108076.html

Form 4 Celularity Inc For: Sep 23 Filed by: Barach Philip Alan

Fri, 25 Sep 2026 16:58:00 -0400

si-local-file:///var/storage/secattach/20260925/27108072.html

Celularity closes $10M+ in financing as part of $28M recapitalization

Thu, 24 Sep 2026 09:15:38 -0400

Celularity Inc. (Nasdaq: CELU) announced an initial closing of more than $10 million in gross cash proceeds through a private placement of senior secured convertible notes and warrants, according to a company statement dated Sept. 24, 2026.

The closing is part of a broader recapitalization plan that contemplates up to $25 million in new cash investment and the restructuring of approximately $3 million in existing debt, bringing the total potential recapitalization to $28 million. Additional closings remain subject to investor election procedures and other conditions, and the company cautioned there is no assurance they will occur.

The notes mature 24 months from

Celularity Announces Over $10 Million Initial Financing Closing as Part of Up to $28 Million Recapitalization to Accelerate Growth Following Significant Operating Improvements

Thu, 24 Sep 2026 09:15:00 -0400

Plan combines up to $25 million in new capital with restructuring of $3 million in existing debt to support commercial execution and manufacturing expansion

Company anticipates positive monthly operating cash flow by the end of Q1 2027

Philip A. Barach to join the Board, bringing financial expertise and a focus on capital discipline

FLORHAM PARK, N.J., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company, today announced an initial closing generating over $10 million in gross cash proceeds from

Celularity Announces Over $10 Million Initial Financing Closing as Part of Up to $28 Million Recapitalization to Accelerate Growth Following Significant Operating Improvements

Thu, 24 Sep 2026 09:15:00 -0400

Plan combines up to $25 million in new capital with restructuring of $3 million in existing debt to support commercial execution and manufacturing expansion

Company anticipates positive monthly operating cash flow by the end of Q1 2027

Philip A. Barach to join the Board, bringing financial expertise and a focus on capital discipline

Form 8-K Celularity Inc For: Sep 11

Mon, 14 Sep 2026 09:01:00 -0400

si-local-file:///var/storage/secattach/20260914/27056301.html

Celularity and MuseCell to produce cell therapies in New Jersey

Thu, 27 Aug 2026 09:01:16 -0400

Celularity Inc. (Nasdaq: CELU) and MuseCell Innovations® Pte. Ltd. announced a manufacturing collaboration under which Celularity will establish U.S. production of Dezawa MuseCells at its Florham Park, New Jersey facility.

The initial program is designed to build manufacturing capability for authenticated Dezawa MuseCell preparations derived from perinatal, bone marrow, and adipose starting materials, produced under the licensed Dezawa Method. The collaboration also covers DMC-derived products, including Dezawa MuseExosomes and Dezawa MuseSecretome.

MuseCell Innovations projects that an expanded relationship could result in more than $300 million in aggregate purchases from Celularity over five years. The company stated this estimate reflects potential future programs

Celularity and MuseCell Innovations® Announce U.S. Manufacturing Collaboration for the Dezawa MuseCell® Platform